Main Page
Faculty Deanship
Dean
Health Empowerment Unit
Strategic Planning Unit
Development and Quality Unit
Medical and Bioethics Unit
Vice Dean for Graduate Studies and Research
Vice Dean for Female Section
Vice dean for Academic Affairs
Examination and Assessment Unit
Internship and Alumni Unit
Student Research Unit
E-learning Unit
Student Mentoring and Support Unit
Community Service Unit
Talent and Creativity Care Unit
Continuing Education Unit
Neuroscience Research Unit
Vice Deanship of Clinical Affairs / Administration
Organizational Structure
Departments
Basic Sciences
Department of Anatomy
Department of Pharmacology
Department of Pathology
Department of Microbiology and Medical Parasitolog
Deparment of Clinical Biochemistry
Department of Physiology
Department of Medical Genetics
Clinical Sciences
Department of Otorhinolaryngology
Department of Obstetrics and Gynecology
Department of Hematology
Department of Medical Education
Department of Anesthesia
Department of Family Medicine
Department of Community Medicine
Department of Surgery
Department of Orthopedic Surgery
Department of ophthalmology
Department of Radiology
Department of Internal Medicine
Department of Pediatrics
Department of Emergency Medicine
Department of Urology
Department of Dermatology
Latest News
عربي
English
About
Admission
Academic
Research and Innovations
University Life
E-Services
Search
Faculty of Medicine
Document Details
Document Type
:
Article In Journal
Document Title
:
Clinical experience with adalimumab in the treatment of ocular Behçet disease
Clinical experience with adalimumab in the treatment of ocular Behçet disease
Subject
:
Ophthalmology
Document Language
:
English
Abstract
:
PURPOSE: To describe the clinical outcome of refractory ocular Behçet disease with adalimumab therapy. METHOD: Retrospective review of records. RESULTS: Twenty-one eyes of 11 male patients with ocular Behçet disease received adalimumab therapy. Of the 21 eyes, 17 had improvement of visual acuity by more than 3 lines after the average follow-up of 10.8 months. Ten out of 11 patients showed complete resolution of inflammation by 4 weeks. The dosages of corticosteroids and immunosuppressive drugs were reduced in most of the patients and stopped altogether in 3 and 6 patients, respectively. One patient on infliximab showed improvement of inflammation after switching over to adalimumab. No serious side effects were observed in any of the patients. CONCLUSION: Adalimumab appears to be effective in Behçet disease. It has been shown to improve visual acuity and also to have a corticosteroid and immunosuppressive sparing effect. It can induce and maintain sustained remission of the disease
ISSN
:
1744-5078
Journal Name
:
Ocular Immunology and Inflammation
Volume
:
18
Issue Number
:
3
Publishing Year
:
1431 AH
2010 AD
Article Type
:
Article
Added Date
:
Tuesday, August 2, 2011
Researchers
Researcher Name (Arabic)
Researcher Name (English)
Researcher Type
Dr Grade
Email
أحمد باوزير
Bawazeer, Ahmed
Investigator
Doctorate
لينا رفه
Raffa, Lina
Researcher
Files
File Name
Type
Description
29996.pdf
pdf
Back To Researches Page